6821 Stock Overview
Asymchem Laboratories (Tianjin) Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Asymchem Laboratories (Tianjin) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥57.40 |
| 52 Week High | CN¥74.50 |
| 52 Week Low | CN¥37.60 |
| Beta | 0.26 |
| 1 Month Change | 2.78% |
| 3 Month Change | 9.75% |
| 1 Year Change | -17.71% |
| 3 Year Change | -65.51% |
| 5 Year Change | n/a |
| Change since IPO | -72.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6821 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 7.9% | 2.6% | 0.6% |
| 1Y | -17.7% | 2.2% | 29.0% |
Return vs Industry: 6821 underperformed the Hong Kong Pharmaceuticals industry which returned 2.2% over the past year.
Return vs Market: 6821 underperformed the Hong Kong Market which returned 29% over the past year.
Price Volatility
| 6821 volatility | |
|---|---|
| 6821 Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 14.3% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 6821 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6821's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 9,300 | Hao Hong | www.asymchem.com.cn |
Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; provision of chemical macromolecule contract development manufacture organization (CDMO) solutions for polypeptides, oligonucleotides, glycans, toxins-linkers and other macromolecules; biosynthesis solutions; biologics CDMO solutions for monoclonal antibodies and antibody-drug conjugates; and contract research organization solutions and messenger RNA solutions.
Asymchem Laboratories (Tianjin) Co., Ltd. Fundamentals Summary
| 6821 fundamental statistics | |
|---|---|
| Market cap | HK$29.55b |
| Earnings (TTM) | HK$825.90m |
| Revenue (TTM) | HK$5.98b |
36.7x
P/E Ratio5.1x
P/S RatioIs 6821 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6821 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.57b |
| Cost of Revenue | CN¥3.24b |
| Gross Profit | CN¥2.33b |
| Other Expenses | CN¥1.56b |
| Earnings | CN¥769.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 2.17 |
| Gross Margin | 41.86% |
| Net Profit Margin | 13.80% |
| Debt/Equity Ratio | 0% |
How did 6821 perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield83%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 10:55 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Asymchem Laboratories (Tianjin) Co., Ltd. is covered by 27 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Yue Gao | Changjiang Securities Co. LTD. |
| Hao Wu | Chasing Securities |